Amicus Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell FOLD and other ETFs, options, and stocks.About FOLD
Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio.
CEOBradley Lewis Campbell
CEOBradley Lewis Campbell
Employees499
Employees499
HeadquartersPrinceton, New Jersey
HeadquartersPrinceton, New Jersey
Founded2002
Founded2002
Employees499
Employees499
FOLD Key Statistics
Market cap2.78B
Market cap2.78B
Price-Earnings ratio-72.33
Price-Earnings ratio-72.33
Dividend yield—
Dividend yield—
Average volume4.46M
Average volume4.46M
High today$9.64
High today$9.64
Low today$8.86
Low today$8.86
Open price$9.00
Open price$9.00
Volume9.65M
Volume9.65M
52 Week high$12.65
52 Week high$12.65
52 Week low$5.51
52 Week low$5.51
FOLD News
Seeking Alpha 46m
Amicus targets $1B combined sales by 2028 as Galafold and Pompe therapies drive record growthEarnings Call Insights Amicus targets $1B combined sales by 2028 as Galafold and Pompe therapies drive record growth Nov. 04, 2025 3:57 PM ET Amicus Therapeutic...
Nasdaq 8h
Amicus Therapeutics Beats Q3 Earnings and Revenue EstimatesAmicus Therapeutics (FOLD) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnin...
Analyst ratings
90%
of 10 ratingsBuy
90%
Hold
10%
Sell
0%
People also own
Based on the portfolios of people who own FOLD. This list is generated using Robinhood data, and it’s not a recommendation.